c-rel

IT-901 is an orally active and potent NF-κB subunit c-Rel inhibitor with IC50 values for NF-κB and c-Rel binding to DNA of 0.1 µM and 3 µM, respectively. IT-901 is a naphthalene thiobarbiturate derivative with antitumor activity and is used for the prevention and treatment of human lymphoma and myeloma.

Cyclopenta[c][1]benzopyran-8-ol, 1,2,3,3a,4,9b-hexahydro-4-(4-hydroxyphenyl)-, (3aR,4S,9bS)-rel- is an estrogen receptor beta (ERβ) agonist.

MI-2 (MALT1 inhibitor) is an irreversible MALT1 inhibitor.

(rel)-Tivantinib is a potent, highly selective inhibitor of the receptor tyrosine kinase c-MET and has additional novel targets, GSK3α and GSK3β, that are critical in the cellular mechanisms of non-small cell lung cancer (NSCLC) [1].

DC-SX029 is a potent inhibitor of SNX10 protein-protein interaction (PPI) with an estimated K D constant of approximately 0.935 μM as measured by surface plasmon resonance (SPR). It blocks the SNX10-PIKfyve interaction, leading to decreased TBK1 c-Rel signaling activation, without affecting SNX10 protein levels. DC-SX029 shows potential for inflammatory bowel disease (IBD) research [1].

(E Z)-IT-603 is a cell-permeable c-Rel inhibitor (IC50: 3μM) that directly and reversibly binds to c-Rel, altering its conformation and inhibiting its DNA binding and transcriptional activity.